AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Proudly Announces the Launch of its Product iPlexus, at Bio-IT World, 2017
Innoplexus unveiled iPlexus at Bio-IT, 2017, Boston. iPlexus.ai is an end-to-end platform for Life Sciences which leverages Artificial Intelligence (AI) to cut the drug development time, from synthesis to approval, significantly. It generates continuous intelligence and insights, across discovery, clinical development, regulatory and commercial stages of drug development, spanning all major therapeutic areas and indications. It has modules for Competitive Intelligence, Clinical Intelligence, Regulatory Intelligence, Gene and Intervention landscapes.
The platform leverages our proprietary CAAV™ framework to crawl, aggregate, analyse, index and visualise hundreds of terabytes of scientific data across hundreds of clinical trial databases, biological databases, major patent offices, congresses, theses, forums and regulatory bodies. It offers confidence that the researcher will not miss any significant information that might impact his/her research later. There is value in getting information readily and as soon as it’s available – more so in research, as it can totally change the path of the work that happens next. A researcher, now with its help, can get real-time access and understanding of the wide variety of research data, and benefit from understanding their cross-pollination.
It offers an easy to use, intuitive, secure, cloud-based system which generates intelligence across datasets using machine learning models, natural language processing and advanced text analytics. Our patent pending data extraction algorithms leverage our Ontologise™ framework to transform raw unstructured data into a structured form. Making data and insights instantly and continuously available takes the pain out of data collection, curation and analysis, eventually helping to make informed decisions better and faster.
iPlexus homes in 35+ million scientific articles, more than 150+ clinical trials databases, over 250+ biological databases, along with major international congresses, patents, etc.
Innoplexus has innovated in the way data is crawled (collected) from thousands of data sources across hundreds of formats of HTMLs, PDFs and other document types. Innoplexus’ technology is now able to leverage Deep Learning and Computer Vision to extract specific data points from unstructured, unlabelled, continuous text as well.
In addition, it is able to disambiguate between entities eg. different authors with same names and leverage our ontology to discover relationships between them.
News source: PRNewswire
This article was originally published on Cision
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
